GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Book Value per Share

WuXi Biologics (Cayman) (FRA:1FW2) Book Value per Share : €1.22 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Book Value per Share?

WuXi Biologics (Cayman)'s book value per share for the quarter that ended in Dec. 2023 was €1.22.

During the past 12 months, WuXi Biologics (Cayman)'s average Book Value Per Share Growth Rate was 11.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 20.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 34.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of WuXi Biologics (Cayman) was 262.10% per year. The lowest was 20.20% per year. And the median was 63.40% per year.

WuXi Biologics (Cayman)'s current price is €1.8158. Its book value per share for the quarter that ended in Dec. 2023 was €1.22. Hence, today's PB Ratio of WuXi Biologics (Cayman) is 1.49.

During the past 10 years, the highest P/B Ratio of WuXi Biologics (Cayman) was 176.07. The lowest was 1.22. And the median was 11.14.


WuXi Biologics (Cayman) Book Value per Share Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Book Value per Share Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.63 1.05 1.12 1.22

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 1.14 1.12 1.15 1.22

Competitive Comparison of WuXi Biologics (Cayman)'s Book Value per Share

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PB Ratio distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s PB Ratio falls into.



WuXi Biologics (Cayman) Book Value per Share Calculation

WuXi Biologics (Cayman)'s Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(5,180-0)/4,258
=1.22

WuXi Biologics (Cayman)'s Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(5,180-0)/4,258
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


WuXi Biologics (Cayman)  (FRA:1FW2) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


WuXi Biologics (Cayman) Book Value per Share Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines